Skip to main content
SpringerLink
Log in

We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

The Original Article was published on 10 January 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

    Article  Google Scholar 

  2. Parikh ND, Marrero WJ, Wang J, et al. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology. 2019;70:487–95.

    Article  CAS  Google Scholar 

  3. Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of monalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017;112:581–7.

    Article  Google Scholar 

  4. Balp M-M, Krieger N, Przybysz R, et al. The burden of nonalcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient-reported outcomes study. JHEP Rep. 2019;1:154–61.

    Article  Google Scholar 

  5. Allen AM, Van Houten HK, Sangaralingham LR, et al. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large US claims database. Hepatology. 2018;68:2230–8.

    Article  Google Scholar 

  6. Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology. 2018;67:1726–36.

    Article  CAS  Google Scholar 

  7. Tapper EB, Lok AS-F. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377:756–68.

  8. Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepatol. 2018;68:362–75.

    Article  CAS  Google Scholar 

  9. Johansen P, Howard D, Bishop R, et al. Systematic literature review and critical appraisal of health economic models used in cost-effectiveness analyses in non-alcoholic steatohepatitis: potential for improvements. Pharmacoeconomics. 2020 Jan 10. https://doi.org/10.1007/s40273-019-00881-7. (Epub ahead of print).

  10. Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology. 2019;70:1913–27.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Michigan, 3912 Taubman, SPC 5362, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA

    Elliot B. Tapper

  2. Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA

    Elliot B. Tapper

  3. Massachusetts General Hospital Institute for Technology Assessment, Harvard Medical School, Boston, MA, USA

    Jagpreet Chhatwal

Authors
  1. Elliot B. Tapper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jagpreet Chhatwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EBT and JC provided the concept for this article and the analysis. EBT wrote the article and JC revised the article. EBT is the guarantor of this article.

Corresponding author

Correspondence to Elliot B. Tapper.

Ethics declarations

Funding

Elliot B. Tapper receives funding from the National Institutes of Health through the NIDDK (1K23DK117055-01A1).

Conflict of interest

Elliot B. Tapper has served as a consultant to Norvartis, Kaleido, and Allergan, has served on advisory boards for Mallinckrodt, Rebiotix, and Bausch Health, and has received unrestricted research grants from Gilead and Valeant. Jagpreet Chhatwal has received research grants from Merck and Gilead, and served as a principal scientist at Value Analytic Labs.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tapper, E.B., Chhatwal, J. We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. PharmacoEconomics 38, 427–429 (2020). https://doi.org/10.1007/s40273-020-00892-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-020-00892-9

Search

Navigation